The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Change from baseline to the week 10 last observation carried forward endpoint in the 17-item HAM-D total score. [ Time Frame: 10 Weeks ]
Secondary Outcome Measures
Mean change from baseline in HAM-D item 1; Mean change from baseline in the CGI severity of illness score at study endpoint; Percentage of patients with HAM-D total score less than or equal to 7. [ Time Frame: 10 Weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
60 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosis of Major Depressive Disorder (MDD).
Current major depressive episode at screen at least 2 months duration.
Must be at least 60 years of age.
Patients with a primary diagnosis other than MDD.
Patients with a history of schizophrenia, schizoaffective disorder, bipolar disorder or dementia.
Patients with a history of brief depressive episodes lasting less than 8 weeks.
Patients receiving formal psychotherapy within 12 weeks of study.
Patients who are suicidal.
Patients who have received electroconvulsive therapy or transcranial magnetic stimulation within 6 months prior to screening.
For additional information about this study please refer to the GSK Clinical Study Register
Publications of Results:
Pitts CD, Schaefer D, Lipschitz A, Iyengar M: Efficacy and Tolerability of Fixed, Low Dose Paroxetine CR in the Treatment of Depression in the Elderly, Poster No. NR701, presented at the American Psychiatric Association Annual Meeting, May 2005. Available at: www.psych.org